

# Silvia Hofer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2792768/publications.pdf>

Version: 2024-02-01

44  
papers

3,389  
citations

448610

19  
h-index

488211

31  
g-index

45  
all docs

45  
docs citations

45  
times ranked

6810  
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptomeningeal metastases from solid tumours. Memo - Magazine of European Medical Oncology, 2021, 14, 192-197.	0.3	2
2	Neuro-oncology 2021. Memo - Magazine of European Medical Oncology, 2021, 14, 132-132.	0.3	0
3	Development of Randomized Trials in Adults with Medulloblastomaâ€”The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	1.7	8
4	Retinoblastoma with late metastatic spreadâ€”a case report. Pediatric Blood and Cancer, 2019, 66, e27656.	0.8	1
5	Complementary and alternative medicine use by glioma patients in Switzerland. Neuro-Oncology Practice, 2019, 6, 237-244.	1.0	8
6	Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Annals of Oncology, 2018, 29, 1431-1436.	0.6	73
7	Angiosarcoma of the scalp responding to nivolumab: a case report. British Journal of Dermatology, 2018, 179, 530-531.	1.4	11
8	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
9	Developments in neuro-oncology. Memo - Magazine of European Medical Oncology, 2018, 11, 161-162.	0.3	0
10	QOLP-27. USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi220-vi220.	0.6	0
11	Letter comments on EJC published article: Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2â€”positive breast carcinomatous meningitis. European Journal of Cancer, 2018, 103, 279-280.	1.3	1
12	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. Journal of Clinical Oncology, 2018, 36, e14062-e14062.	0.8	0
13	memo: Spectacular developments during the last decade from the Section Editorsâ€™ point of view. Memo - Magazine of European Medical Oncology, 2017, 10, 4-7.	0.3	0
14	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer, 2016, 122, 2206-2215.	2.0	77
15	Chemotherapy for intracranial ependymoma in adults. BMC Cancer, 2016, 16, 287.	1.1	23
16	Intravascular large Bâ€”cell lymphoma. Memo - Magazine of European Medical Oncology, 2016, 9, 59-62.	0.3	0
17	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-Oncology, 2016, 18, 744-751.	0.6	58
18	BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA). Acta Oncologica, 2016, 55, 122-123.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Efficacy of Surgery and Further Treatment of Progressive Glioblastoma. <i>World Neurosurgery</i> , 2015, 84, 301-307.	0.7	39
20	Complement Activation and Rituximab Distribution in CNS NHL Letter. <i>Clinical Cancer Research</i> , 2015, 21, 490-490.	3.2	3
21	Prevalence and predictors of fatigue in glioblastoma: a prospective study. <i>Neuro-Oncology</i> , 2015, 17, 274-281.	0.6	47
22	Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). <i>British Journal of Cancer</i> , 2015, 113, 716-721.	2.9	23
23	Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009).. <i>Journal of Clinical Oncology</i> , 2015, 33, e13025-e13025.	0.8	2
24	P18.01 * COMPLEMENTARY THERAPY USE IN A COHORT OF SWISS GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2014, 16, ii110-ii110.	0.6	0
25	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	7.7	627
26	Molecular biology of high-grade gliomas: what should the clinician know?. <i>Chinese Journal of Cancer</i> , 2014, 33, 4-7.	4.9	24
27	Neurooncology: current findings and challenges for the future. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 225-226.	0.3	0
28	Update on neurooncology Annual meeting of the American Society of Clinical Oncology (ASCO) 2013. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 247-250.	0.3	0
29	Treatment of breast cancer brain metastases. <i>European Journal of Pharmacology</i> , 2013, 717, 84-87.	1.7	12
30	Intrathecal trastuzumab: dose matters. <i>Acta Oncologica</i> , 2012, 51, 955-956.	0.8	20
31	Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial. <i>Oncology</i> , 2012, 83, 1-9.	0.9	41
32	News from the Neuro-Oncology front. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 169-170.	0.3	0
33	Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 210-217.	0.3	0
34	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011, 50, 630-635.	0.8	38
35	Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib A Phase II Trial. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1102-1112.	1.9	170
36	Targeted therapies on the horizon for malignant glioma. <i>Targeted Oncology</i> , 2010, 5, 157-160.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Molecular markers in gliomas: impact for the clinician. <i>Targeted Oncology</i> , 2010, 5, 201-210.	1.7	21
38	Chemotherapy maintenance: An option for prolonged survival in malignant peritoneal mesothelioma?. <i>Acta Oncologica</i> , 2010, 49, 125-127.	0.8	3
39	Evolution of glioblastoma. <i>Acta Oncologica</i> , 2009, 48, 630-631.	0.8	1
40	Early metabolic responses in temozolomide treated low-grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2009, 95, 87-93.	1.4	94
41	Gefitinib concentrations in human glioblastoma tissue. <i>Journal of Neuro-Oncology</i> , 2007, 82, 175-176.	1.4	35
42	Gefitinib accumulation in glioblastoma tissue. <i>Cancer Biology and Therapy</i> , 2006, 5, 483-484.	1.5	23
43	Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 239-239.	1.4	0
44	Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC). <i>Swiss Medical Weekly</i> , 2001, 131, 640-4.	0.8	12